/
Genelux is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat tumor types. Our clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient s tumor neoantigens.
The business is unprofitable at the operating level (-415175.00% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 0.0% YoY. Margins deteriorated 18975.0pp alongside, both lines moving the wrong way.
ROIC dropped from -98.13% to -126.85%, capital efficiency is deteriorating. Negative free cash flow of -$26M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$8K
Net Income (TTM)
-$34M
▼ -7.6% YoY
Op. Margin
-415175.00%
▼ -18975.0pp YoY
ROIC
-129.33%
▼ -28.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$28M
▼ -22.0% YoY
Op. Cash Flow (TTM)
-$26M
▼ -19.0% YoY
Net Debt
-$24M
Net Cash Position
Cash & Equiv.
$26M
3Y CAGR: -91.0%
Continue Research